Soren Gade Jensen - Net Worth and Insider Trading

Soren Gade Jensen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Soren Gade Jensen owns 1 companies in total, including Allarity Therapeutics Inc (ALLR) .

Click here to see the complete history of Soren Gade Jensen’s form 4 insider trades.

Insider Ownership Summary of Soren Gade Jensen

Ticker Comapny Transaction Date Type of Owner
ALLR Allarity Therapeutics Inc 2021-12-20 director

Soren Gade Jensen Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Soren Gade Jensen Ownership Network

Ownership Network List of Soren Gade Jensen

No Data

Ownership Network Relation of Soren Gade Jensen

Insider Network Chart

Soren Gade Jensen Owned Company Details

What does Allarity Therapeutics Inc do?

Who are the key executives at Allarity Therapeutics Inc?

Soren Gade Jensen is the director of Allarity Therapeutics Inc. Other key executives at Allarity Therapeutics Inc include Chief Financial Officer Joan Yvonne Brown , director & Chief Executive Officer Steve Carchedi , and Chief Scientific Officer Steen Knudsen .

Allarity Therapeutics Inc (ALLR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Allarity Therapeutics Inc (ALLR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Allarity Therapeutics Inc (ALLR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Allarity Therapeutics Inc (ALLR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Allarity Therapeutics Inc Insider Transactions

No Available Data

Soren Gade Jensen Mailing Address

Above is the net worth, insider trading, and ownership report for Soren Gade Jensen. You might contact Soren Gade Jensen via mailing address: 210 Broadway, Ste 201, Cambridge Ma 02139.

Discussions on Soren Gade Jensen

No discussions yet.